[Code of Federal Regulations]

[Title 40, Volume 23]

[Revised as of July 1, 2006]

From the U.S. Government Printing Office via GPO Access

[CITE: 40CFR158.340]



[Page 103-106]

 

                   TITLE 40--PROTECTION OF ENVIRONMENT

 

         CHAPTER I--ENVIRONMENTAL PROTECTION AGENCY (CONTINUED)

 

PART 158_DATA REQUIREMENTS FOR REGISTRATION--Table of Contents

 

                    Subpart D_Data Requirement Tables

 

Sec.  158.340  Toxicology data requirements.



    (a) Table. Sections 158.50 and 158.100 through 158.102 describe how 

to use this table to determine the toxicology data requirements and the 

substance to be tested.



[[Page 104]]







------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

                                                                                    General use patterns                                                    Test substance

                                          ------------------------------------------------------------------------------------------------------------------------------------------- Guidelines

     Kind of data required      (b) Notes        Terrestrial               Aquatic              Greenhouse                                                                             reference

                                          ----------------------------------------------------------------------  Forestry   Domestic    Indoor    Data to support   Data to support      No.

                                            Food crop    Nonfood    Food crop    Nonfood   Food crop   Nonfood               outdoor                     MP                EP

------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

         Acute testing



Acute oral toxicity--rat......        (1)  [R]         [R]         [R]         [R]         [R]        [R]        [R]        [R]        [R]        MP and TGAI.....  EP* or EP               81-1

                                                                                                                                                                     dilution* and

                                                                                                                                                                     TGAI.

Acute dermal toxicity.........   (1), (2)  [R]         [R]         [R]         [R]         [R]        [R]        [R]        [R]        [R]        MP and TGAI.....  EP* or EP               81-2

                                                                                                                                                                     dilution* and

                                                                                                                                                                     TGAI.

Acute inhalation toxicity--rat       (16)  [R]         [R]         [R]         [R]         [R]        [R]        [R]        [R]        [R]        MP and TGAI.....  EP* and TGAI....        81-3

Primary eye irritation--rabbit        (2)  [R]         [R]         [R]         [R]         [R]        [R]        [R]        [R]        [R]        MP..............  EP*.............        81-4

Primary dermal irritation.....   (1), (2)  [R]         [R]         [R]         [R]         [R]        [R]        [R]        [R]        [R]        MP..............  EP*.............        81-5

Dermal sensitization..........        (3)  [R]         [R]         [R]         [R]         [R]        [R]        [R]        [R]        [R]        MP..............  EP*.............        81-6

Acute delayed neurotoxicity--         (4)  [R]         [R]         [R]         [R]         [R]        [R]        [R]        [R]        [R]        TGAI............  TGAI............        81-7

 hen.



      Subchronic testing



90-day feeding studies--rodent       (17)  [R]         CR          [R]         CR          [R]        CR         CR         CR         CR         TGAI............  TGAI............        82-1

 and nonrodent.

21-day dermal.................       (18)  CR          CR          CR          CR          CR         CR         CR         CR         CR         TGAI............  TGAI and EP*....        82-2

90-day dermal.................  (5), (19)  CR          CR          CR          CR          CR         CR         CR         CR         CR         TGAI............  TGAI............        82-3

90-day inhalation--rat                (6)  CR          CR          CR          CR          CR         CR         CR         CR         CR         TGAI............  TGAI............        82-4

90-day neurotoxicity:

  Hen.........................        (7)  CR          CR          CR          CR          CR         CR         CR         CR         CR         TGAI............  TGAI............        82-5

  Mammal......................        (8)  CR          CR          CR          CR          CR         CR         CR         CR         CR         TGAI............  TGAI............        82-5



        Chronic testing



Chronic feeding--2 spp. rodent       (9),  [R]         CR          [R]         CR          [R]        CR         CR         CR         CR         TGAI............  TGAI............        83-1

 and nonrodent.                     (13),

                                     (20)

Oncogenicity study--2 Spp. rat  (9), (21)  R           CR          R           CR          R          CR         CR         CR         CR         TGAI............  TGAI............        83-2

 and mouse preferred.

Teratogenicity--2 species.....      (10),  [R]         CR          [R]         CR          [R]        CR         CR         CR         CR         TGAI............  TGAI............        83-3

                                     (15)

Reproduction, 2-generation....      (11),  [R]         CR          [R]         CR          [R]        CR         CR         CR         CR         TGAI............  TGAI............        83-4

                                     (14)



     Mutagenicity testing



Gene mutation.................       (22)  [R]         R           [R]         R           [R]        R          R          R          R          TGAI............  TGAI............        84-2

Structural chromosomal               (22)  [R]         R           [R]         R           [R]        R          R          R          R          TGAI............  TGAI............        84-2

 aberration.

Other genotoxic effects.......       (22)  [R]         R           [R]         R           [R]        R          R          R          R          TGAI............  TGAI............        84-4





[[Page 105]]





        Special testing



General metabolism............       (23)  R           CR          R           CR          R          CR         CR         CR         CR         PAI or PAIRA....  PAI or PAIRA....        85-1

Dermal penetration............       (24)  CR          CR          CR          CR          CR         CR         CR         CR         CR         Choice..........  Choice..........        85-2

Domestic animal safety........       (12)  CR          CR          CR          CR          .........  .........  CR         CR         .........  Choice..........  Choice..........        86-1

------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

 AAAKey: R=Required data; CR=Conditionally required; [ ]=Brackets (ie [R], [CR] indicate data requirements that apply when an experimental use permit is being sought; MP=manufacturing-use

  product; EP*=End-Use Product; (asterisk identifies those data requirements that end-use applicants (i.e., ``formulators'') must satisfy, provided that their active ingredient(s) is (are)

  purchased from a registered source); TGAI=Technical grade of the active ingredient; PAI=``Pure'' active ingredient; PAIRA=``Pure'' active ingredient, radio-labeled; Choice=choice of several

  test substances, depending on studies required.

(b) Notes. The following notes are referenced in column two of the table contained in paragraph (a) of this section.

(1) Not required if test material is a gas or highly volatile.

(2) Not required if test material is corrosive to skin or has pH less than 2 or greater than 11.5; such a product will be classified as toxicity category I on the basis of potential eye and

  dermal irritation effects.

(3) Required unless repeated dermal exposure does not occur under conditions of use.

(4) Not required unless test material, is an organophosphate, or a metabolite or degradation product thereof which causes acetyl cholinesterase depression or is structurally related to a

  substance that causes delayed neurotoxicity.

(5) Required if use involves purposeful dermal application to, or prolonged exposure of, human skin.

(6) Required if use may result in repeated inhalation exposure at a concentration likely to be toxic. A test with duration of 21 days is required if pesticide is used on tobacco.

(7) Required if acute delayed neurotoxicity test showed neuropathy or neurotoxicity or if closely related structural to a compound which can induce these effects.

(8) Required if acute oral, dermal, or inhalation studies showed neuropathy or neurotoxicity.

(9)(i) Studies designed to simultaneously meet the requirements of both the chronic feeding and oncogenicity studies (i.e., a combined study) can be conducted.

(ii) Minimum acceptable test durations for chronic feeding and oncogenicity studies are as follows:

(A) Chronic rodent feeding study (food use pesticides)--24 months.

(B) Chronic rodent feeding study (non-food pesticides)--12 months is usually sufficient.

(C) Chronic nonrodent (i.e., dog) feeding study--12 months.

(D) Mouse oncogenicity study--18 months.

(E) Rat oncogenicity study--24 months.

(10) Required to support products intended for food uses and to supoort products intended for non-food uses if significant exposure of human females of child bearing age may reasonably be

  expected.

(11) Required to support products intended for food uses and to support products intended for non-food uses if use of the product is likely to result in human exposure over a portion of the

  human lifespan which is significant in terms of the frequency of exposure, magnitude of exposure, or the duration of exposure (for example; pesticides used in treated fabrics for wearing

  apparel, diapers, or bedding; insect repellents applied directly to human skin; swimming pool additives; constant-release indoor pesticides which are used in aerosol form).

(12) Required on a case by case basis.

(13) In most cases, where theoretical maximum residue contribution (TMRC) exceeds 50 percent of the maximum permitted intake (MPI), a one year (or longer) interim report on a chronic feed

  study is required to support a temporary tolerance.

(14) In most cases, where theoretical maxium residue contribution (TMRC) exceeds 50 percent of the maxium permitted intake (MPI), a first generation (or longer) interim report on a

  multigeneration reproduction study is required to support a temporary tolerance.

(15) A teratology study in one species is required to support a temporary tolerance.

(16) Required if the product consists of, or under conditions of use will result in, an inhalable material (e.g., gas volatile substances, or aerosol/particulate).

(17) Required if intended use(s) of the pesticide product is expected to result in human exposure to the product, under the following conditions:

(i) Human exposure is via the oral route.

(ii) Expected human exposure is over a limited portion of the human lifespan, yet is significant in terms of the frequency of exposure, magnitude of exposure, or the duration of exposure (for

  example, products requiring a temporary tolerance to support an experimental use permit or emergency exemption).

(18) Required if intended use(s) of the pesticide product is expected to result in human exposure to the product, under the following conditions:

(i) Human exposure is via skin contact.

(ii) Expected human skin contact is not purposeful, and such exposure is of limited frequence and duration (for example, such exposure could result from use of certain disinfectant, liquid

  fumigant or agricultural or home/garden pesticide products, and other circumstances where the Agency determines that more than acute dermal exposure is involved).

(iii) Data from a subchronic 90-day dermal toxicity study are not required.

(19) Required if pesticidal use will involve purposeful application to the human skin or will result in comparable human exposure to the product, (e.g., swimming pool algaecides, pesticides

  for impregnating clothing), and if either of the following criteria are met:

(i) Data from a subchronic oral study are not required.

(ii) The active ingredient of the product is known or expected to be metabolized differently by the dermal route of exposure than by the oral route, and a metabolite of the active ingredient

  is the toxic moiety.

(20) Required if either of the following criteria are met:

(i) Use of the pesticide product is likely to result in repeated human exposure to the product, over a significant portion of the human life-span (for example, products intended for use in and

  around residences, swimming pools, and enclosed working spaces or their immediate vicinity).



[[Page 106]]





(ii) The use requires a tolerance for the pesticide or an exemption from the requirement to obtain a tolerance, or requires issuance of a food additive regulation.

(21) Required if any of the following criteria are met:

(i) The active ingredient(s) or any of its (their) metabolites, degradation products, or impurities:

(A) Is structually related to a recognized carcinogen.

(B) Is a substance that cause mutagenic effect as demonstrated by in vitro or in vivo testing.

(C) Produces in subchronic studies a morphologic effect (e.g., hyperplasia, metaplasia) in any organ that may lead to neoplastic change.

(ii) The use requires a tolerance for the pesticide or exemption from the requirement to obtain a tolerance, or requires the issuance of a food additive regulation.

(iii) Use of the pesticide product is likely to result in human exposure over a portion of the human lifespan which is significant in terms of either the time the exposure occurs or the

  duration of exposure (for example; pesticides used in treated fabrics for wearing apparel, diapers, or bedding; insect repellents applied directly to human skin; swimming pool additives;

  constant-release indoor pesticides which are used in aerosol form).

(22)(i) The required battery of mutagenicity tests must include tests appropriate to address the following three categories in accordance with the objectives set forth in Sec.   158.202:

(A) Gene mutations.

(B) Structural chromosomal aberrations.

(C) Other genotoxic effects as appropriate for the test substance, e.g., numerical chromosome abberations, direct DNA damage and repair, mammalian cells transformation, target organ/cell

  analysis.

(ii) Currently recognized tests for each of these categories are listed with the National Technical Information Service (NTIS). Applicants shall explain their reasons for selecting specific

  tests from the battery of currently recognized tests. Because of the rapid improvements in this field, applicants are encouraged to discuss with the Agency: test selection, protocol design

  and results of preliminary testing.

(iii) Not required if the pesticide use pattern precludes human exposure (e.g., nonvolatile pesticides packaged and used in enclosed bait boxes).

(23) Required if chronic feeding or oncogenicity studies are required.

(24) Dermal absorption studies required for compounds having a serious toxic effect as identified by oral or inhalation studies, for which a significant route of human exposure is dermal and

  for which the assumption of 100 percent absorption does not produce an adequate margin of safety. Registrants should work closely with the Agency in developing an acceptable protocol and

  performing dermal absorption studies.





[49 FR 42881, Oct. 24, 1984. Redesignated and amended at 53 FR 15993, 

15999, May 4, 1988; 58 FR 34203, June 23, 1993]